BrainsWay Reports Q3 2019 Financial Results

- November 25th, 2019

The company has reported its financial results for the third quarter ended September 30 in addition to a corporate update.

BrainsWay (NASDAQ:BWAY, TASE:BWAY) has reported its Q3 financial results for the quarter ended SEptember 30, 2019.

As quoted in the press release:

“We are pleased with our solid performance in the third quarter of this year,” said Dr. David Zacut, Chairman, Interim CEO and a founder of BrainsWay. “These positive results reflect the continued increase in demand for our Deep Transcranial Magnetic Stimulation system (Deep TMS) and the sustained momentum of our business during the Company’s strategic transition to U.S.-based leadership, which began during the third quarter with the relocation of our Chief Financial Officer and Chief Operations Officer, Hadar Levy, to New Jersey. Our third quarter performance is further notable in light of the seasonality typically associated with this quarter. We look forward to continuing to implement our growth strategy through our focus on commercial excellence and scientific advancement.”

Financial Results for the Third Quarter Ended September 30, 2019

Quarterly record revenue of $5.9 million, an increase of 38% over the third quarter of 2018.

Recurring revenues of $3.4 million, an increase of 40% over the third quarter of 2018.

Since September 30, 2018, BrainsWay’s installed base has increased by 138, reaching an all-time high of 488 Deep TMS systems and reflecting a quarter-over-quarter increase of 32 systems.

As of September 30, 2019, the Company has shipped 132 OCD coils as add-on helmets to certain of BrainsWay’s new and existing systems since marketing clearance was obtained in August 2018.

Gross margin for the third quarter of 2019 was 81%, compared to 78% during the third quarter of 2018.

Research and development (R&D) expenses for the quarter were $1.9 million, compared to $1.4 million in the same period in 2018. The increase was due to the continued development of BrainsWay’s proprietary Deep TMS technology, including completion of the smoking cessation study and conducting clinical trials for the treatment of post-traumatic stress disorder and other brain disorders.

Sales and marketing expenses for the quarter were $3.5 million, compared to $2.0 million in the same period in 2018. The increase was primarily driven by an expansion of the sales force and enhanced marketing activities for both MDD and OCD.

General and administrative expenses for the quarter were $1.5 million, compared to $0.9 million for the same period in 2018. The increase was due to additional costs associated with BrainsWay being a public company in the U.S. and an increase in an allowance for doubtful accounts.

Operating expenses totaled $7.0 million, compared to $4.3 million in the third quarter of 2018. The increase was primarily driven by the enhanced sales and marketing activities, and the increase in R&D expenses, as well as the increased general and administrative costs incurred following BrainsWay’s IPO in the U.S.

Click here to read the full press release.

Read our new 2019 medical device report today

 

 

Including: 3+ stocks to watch as well as valuable market data   Get My Free Report Click here to download for free

Leave a Reply

Your email address will not be published. Required fields are marked *